
Sean P. Gramling
Examiner (ID: 3948, Phone: (571)272-9082 , Office: P/2875 )
| Most Active Art Unit | 2875 |
| Art Unit(s) | 2809, 2112, 2875 |
| Total Applications | 1285 |
| Issued Applications | 833 |
| Pending Applications | 63 |
| Abandoned Applications | 412 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17664177
[patent_doc_number] => 11357853
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-14
[patent_title] => Inhibition of a lncRNA for treatment of neuroblastoma
[patent_app_type] => utility
[patent_app_number] => 16/965876
[patent_app_country] => US
[patent_app_date] => 2019-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 37
[patent_no_of_words] => 7603
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965876
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/965876 | Inhibition of a lncRNA for treatment of neuroblastoma | Jan 23, 2019 | Issued |
Array
(
[id] => 14994361
[patent_doc_number] => 20190316138
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-17
[patent_title] => OLIGONUCLEOTIDE COMPOSITIONS WITH ENHANCED EFFICIENCY
[patent_app_type] => utility
[patent_app_number] => 16/253180
[patent_app_country] => US
[patent_app_date] => 2019-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22219
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16253180
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/253180 | Oligonucleotide compositions with enhanced efficiency | Jan 20, 2019 | Issued |
Array
(
[id] => 18526475
[patent_doc_number] => 11713463
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-01
[patent_title] => Compositions and methods for increasing expression of SCN2A
[patent_app_type] => utility
[patent_app_number] => 16/962796
[patent_app_country] => US
[patent_app_date] => 2019-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10896
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16962796
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/962796 | Compositions and methods for increasing expression of SCN2A | Jan 16, 2019 | Issued |
Array
(
[id] => 15102661
[patent_doc_number] => 10472632
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-11-12
[patent_title] => Anti-connexin compounds targeted to connexins and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/241943
[patent_app_country] => US
[patent_app_date] => 2019-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 17
[patent_no_of_words] => 34235
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16241943
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/241943 | Anti-connexin compounds targeted to connexins and methods of use thereof | Jan 6, 2019 | Issued |
Array
(
[id] => 15210457
[patent_doc_number] => 20190367915
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => Method for Assaying MicroRNA, Cancer Therapeutic Agent, and Medical Composition Containing Same for Cancer Therapy
[patent_app_type] => utility
[patent_app_number] => 16/241269
[patent_app_country] => US
[patent_app_date] => 2019-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14489
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16241269
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/241269 | Method for assaying MicroRNA, cancer therapeutic agent, and medical composition containing same for cancer therapy | Jan 6, 2019 | Issued |
Array
(
[id] => 14227067
[patent_doc_number] => 20190125706
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-02
[patent_title] => TREATMENT AND DIAGNOSIS OF COLON CANCER
[patent_app_type] => utility
[patent_app_number] => 16/240123
[patent_app_country] => US
[patent_app_date] => 2019-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20362
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16240123
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/240123 | Treatment and diagnosis of colon cancer | Jan 3, 2019 | Issued |
Array
(
[id] => 14897565
[patent_doc_number] => 20190292548
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-26
[patent_title] => Methods Of Identifying And Treating Poor-Prognosis Cancers
[patent_app_type] => utility
[patent_app_number] => 16/230098
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41323
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230098
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/230098 | Methods of identifying and treating poor-prognosis cancers | Dec 20, 2018 | Issued |
Array
(
[id] => 18559972
[patent_doc_number] => 11725208
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-15
[patent_title] => Conjugated antisense compounds and their use
[patent_app_type] => utility
[patent_app_number] => 16/771620
[patent_app_country] => US
[patent_app_date] => 2018-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19914
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 193
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16771620
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/771620 | Conjugated antisense compounds and their use | Dec 13, 2018 | Issued |
Array
(
[id] => 16686756
[patent_doc_number] => 20210069231
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => PHARMACEUTICAL CARRIERS CONTAINING miRNAs FOR USE IN THE TREATMENT OF RENAL CANCER
[patent_app_type] => utility
[patent_app_number] => 16/772280
[patent_app_country] => US
[patent_app_date] => 2018-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5649
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772280
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/772280 | Pharmaceutical carriers containing miRNAs for use in the treatment of renal cancer | Dec 13, 2018 | Issued |
Array
(
[id] => 15086955
[patent_doc_number] => 20190338288
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => MODULATION OF TMPRSS6 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 16/213242
[patent_app_country] => US
[patent_app_date] => 2018-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21857
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213242
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/213242 | MODULATION OF TMPRSS6 EXPRESSION | Dec 6, 2018 | Abandoned |
Array
(
[id] => 14778627
[patent_doc_number] => 20190264211
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => MODULATION OF GENE EXPRESSION AND SCREENING FOR DEREGULATED PROTEIN EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 16/213535
[patent_app_country] => US
[patent_app_date] => 2018-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37882
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213535
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/213535 | Modulation of gene expression and screening for deregulated protein expression | Dec 6, 2018 | Issued |
Array
(
[id] => 16468509
[patent_doc_number] => 20200370046
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => ANGELMAN SYNDROME ANTISENSE TREATMENT
[patent_app_type] => utility
[patent_app_number] => 16/767916
[patent_app_country] => US
[patent_app_date] => 2018-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17937
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16767916
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/767916 | Angelman syndrome antisense treatment | Nov 29, 2018 | Issued |
Array
(
[id] => 15024017
[patent_doc_number] => 20190323013
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-24
[patent_title] => ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/204866
[patent_app_country] => US
[patent_app_date] => 2018-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30093
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16204866
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/204866 | ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF | Nov 28, 2018 | Abandoned |
Array
(
[id] => 14278089
[patent_doc_number] => 20190136329
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-09
[patent_title] => METHODS OF DETECTING TUMOR CELLS
[patent_app_type] => utility
[patent_app_number] => 16/201784
[patent_app_country] => US
[patent_app_date] => 2018-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24794
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16201784
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/201784 | Methods of detecting tumor cells | Nov 26, 2018 | Issued |
Array
(
[id] => 14342953
[patent_doc_number] => 20190153449
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-23
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/195185
[patent_app_country] => US
[patent_app_date] => 2018-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22080
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16195185
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/195185 | Compositions and methods for treating cancer | Nov 18, 2018 | Issued |
Array
(
[id] => 18642349
[patent_doc_number] => 11766402
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-26
[patent_title] => Methods for production of MSC-derived exosomes
[patent_app_type] => utility
[patent_app_number] => 16/762439
[patent_app_country] => US
[patent_app_date] => 2018-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 24
[patent_no_of_words] => 18966
[patent_no_of_claims] => 37
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16762439
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/762439 | Methods for production of MSC-derived exosomes | Nov 15, 2018 | Issued |
Array
(
[id] => 17028570
[patent_doc_number] => 11090368
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-17
[patent_title] => MRNA therapy for Pompe disease
[patent_app_type] => utility
[patent_app_number] => 16/191017
[patent_app_country] => US
[patent_app_date] => 2018-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 9
[patent_no_of_words] => 20337
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16191017
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/191017 | MRNA therapy for Pompe disease | Nov 13, 2018 | Issued |
Array
(
[id] => 16399129
[patent_doc_number] => 20200339987
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => ASSAYS AND METHODS FOR DETERMINING EXPRESSION OF THE LECT2 GENE
[patent_app_type] => utility
[patent_app_number] => 16/762546
[patent_app_country] => US
[patent_app_date] => 2018-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40692
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -189
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16762546
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/762546 | ASSAYS AND METHODS FOR DETERMINING EXPRESSION OF THE LECT2 GENE | Nov 7, 2018 | Abandoned |
Array
(
[id] => 18478272
[patent_doc_number] => 11692002
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-04
[patent_title] => RNA sequence adaptation
[patent_app_type] => utility
[patent_app_number] => 16/762081
[patent_app_country] => US
[patent_app_date] => 2018-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 19
[patent_no_of_words] => 44929
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 148
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16762081
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/762081 | RNA sequence adaptation | Nov 7, 2018 | Issued |
Array
(
[id] => 14914083
[patent_doc_number] => 10428350
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-10-01
[patent_title] => Methods and compositions for the activation of gamma-delta T-cells
[patent_app_type] => utility
[patent_app_number] => 16/182443
[patent_app_country] => US
[patent_app_date] => 2018-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 21530
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16182443
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/182443 | Methods and compositions for the activation of gamma-delta T-cells | Nov 5, 2018 | Issued |